Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Deloitte
Teva
McKesson
Chinese Patent Office
Moodys
Argus Health
Healthtrust
Fish and Richardson
Cerilliant

Generated: October 21, 2017

DrugPatentWatch Database Preview

Celgene Corp Company Profile

« Back to Dashboard

What is the competitive landscape for CELGENE CORP, and what generic alternatives to CELGENE CORP drugs are available?

CELGENE CORP has two approved drugs.

There are twelve US patents protecting CELGENE CORP drugs.

There are one hundred and thirteen patent family members on CELGENE CORP drugs in thirty-one countries.

Summary for Applicant: Celgene Corp

International Patents:113
US Patents:12
Tradenames:2
Ingredients:2
NDAs:2
Drug Master File Entries: (click here to view)2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene Corp
IDHIFA
enasidenib mesylate
TABLET;ORAL209606-001Aug 1, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-003Mar 21, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Celgene Corp
IDHIFA
enasidenib mesylate
TABLET;ORAL209606-001Aug 1, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-002Mar 21, 2014RXYesNo► Subscribe► Subscribe ► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-001Mar 21, 2014RXYesNo► Subscribe► Subscribe ► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-003Mar 21, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-002Mar 21, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-002Mar 21, 2014RXYesNo► Subscribe► Subscribe ► Subscribe
Celgene Corp
IDHIFA
enasidenib mesylate
TABLET;ORAL209606-002Aug 1, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-001Mar 21, 2014RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Celgene Corp

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,659,303Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-1,3-dione► Subscribe
6,011,050 Substituted phenethylsulfones and method of reducing TNF.alpha. levels► Subscribe
9,656,999Therapeutically active compounds and their methods of use► Subscribe
9,283,207Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione► Subscribe
9,433,606Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, compositions thereof, and uses thereof► Subscribe
9,724,330Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione► Subscribe
7,358,272Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione► Subscribe
7,507,759Methods of using(+)-2-[1-(3-ethoxy-4methoxyphenyl)-2-methylsulfonylethyl]-- 4-acetylaminoisoindoline-1,3,-dione► Subscribe
8,093,283Solid forms comprising (+)-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisi- noline-1,3-dione, compositions thereof, and uses thereof► Subscribe
7,276,529Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Celgene Corp Drugs

Country Document Number Estimated Expiration
Japan2005525386► Subscribe
Japan2013047262► Subscribe
South Korea20100040938► Subscribe
South Korea101263786► Subscribe
Chile2016000263► Subscribe
Japan2016527279► Subscribe
Australia1447200► Subscribe
Singapore11201403878Q► Subscribe
Philippines12016500164► Subscribe
Costa Rica20140377► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Baxter
Accenture
Fish and Richardson
Novartis
Colorcon
Johnson and Johnson
UBS
Argus Health
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot